检查点抑制剂相关免疫不良反应的生物标记物研究进展

Progress in Biomarkers for Checkpoint Inhibitor-associated Immune Adverse Events

免疫检查点抑制剂可使多种癌症得到持久缓解,是免疫治疗的重要进展。然而,该类抑制剂相关的免疫性不良反应发生率较高,甚至可能危及生命,因此发现用于检测不良反应的相关生物标记物有重要的临床意义。本文概述了有潜力预测和诊断检查点抑制剂相关免疫不良反应的生物标记物的最新进展,为临床医生评估用药风险和预警不良反应提供参考。

Immune checkpoint inhibitors are important advances in immunotherapy which can achieve long-term remission in a variety of cancers.However,immune checkpoint inhibitors often elicit immune-related adverse events which may result in substantial morbidity.So it is of great clinical significance to find biomarkers for the detection of adverse reactions.This paper summarizes the research progress on biomarkers for checkpoint inhibitor-associated immune adverse events to provide reference for clinicians to assess the risk of medication and early warning of adverse reactions.